at www.tipranks.com (Wed, 11-Mar 9:30 AM)
at www.tipranks.com (Wed, 11-Mar 8:20 AM)
Artiva: Sufficient Cash Runway to 2027 Supports Buy Rating Ahead of Key 2026 RA Efficacy Readouts
at www.tipranks.com (Wed, 11-Mar 6:55 AM)
Artiva: De-Risking RA Opportunity With AlloNK and Fast-Track Path Supports Buy Rating
at www.tipranks.com (Wed, 11-Mar 6:35 AM)
at www.tipranks.com (Tue, 10-Mar 7:10 PM)
Artiva Biotherapeutics GAAP EPS of -$3.43
at seekingalpha.com (Tue, 10-Mar 4:21 PM)